CytomX Therapeutics (CTMX) · varsetatug masetecan / CX-2051
Narrower window · A neutral label from comparing the two stated windows. It says nothing about the program’s results.
Before
Stated timing: second half of 2026
Additional Phase 1 Varseta-M data, including data from ongoing dose optimization, is anticipated to be presented in the second half of 2026.
EX-99.1 · filed · SEC filing
After
Stated timing: by the end of 2026
Additional Phase 1 Varseta-M data, including data from ongoing dose optimization, is anticipated to be presented by the end of 2026.
· filed · SEC filing
Data as of . Both sentences are quoted from the SEC filings linked above and matched to them.
Source: ORION, orionbiotechai.com/changes/CTMX-varsetatug-masetecan-cx-2051-2026-08-06, data as of Oct 13, 2026
https://www.orionbiotechai.com/changes/CTMX-varsetatug-masetecan-cx-2051-2026-08-06
CytomX Therapeutics (CTMX) pipeline and stated timing · Calendar · Companies A–Z
A Form 10-Q is a company’s quarterly report to the SEC, with unaudited financial statements.